NeuroAge Therapeutics
PrivateLast Round
Pre Seed
Feb 16, 2026
Total Funding Raised
$449,817
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NeuroAge Therapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Pre Seed round in February 2026.
NeuroAge Therapeutics is a biotechnology company that operates a platform to assess and reverse brain aging, helping reduce the risk of neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeuroAge Therapeutics Comparables
Compare NeuroAge Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BrainKey | 76% | |
| Linus Health | 64% | |
| AcroViz | 64% |
For institutional investors. Book with your work email.
NeuroAge Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Feb 16, 2026 | ||||
| Grant | Feb 1, 2024 | ||||
| Accelerator | Nov 1, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeuroAge Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Propel(x) | Pre Seed |
| Gates Ventures | Pre Seed |
| R42 Group | Pre Seed |
| Alzheimer's Drug Discovery Foundation | Pre Seed, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 187% MoM, reaching 13K.
- Jul 27, 2026
Monthly visitors increased 63% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 5, 2026
NeuroAge Therapeutics, Inc. develops a platform that combines cognitive assessments, brain MRI, genetic analysis, DEXA body composition imaging, and blood biomarkers into a single NeuroAge Score.
For institutional investors. Book with your work email.
NeuroAge Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeuroAge Therapeutics's valuation, stock price, and market status.
Is NeuroAge Therapeutics a public or private company?
NeuroAge Therapeutics is a private company.
What is the current stock price of NeuroAge Therapeutics?
NeuroAge Therapeutics is a private company, so its shares have no public market price. Caplight tracks NeuroAge Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeuroAge Therapeutics worth (valuation)?
Valuation information for NeuroAge Therapeutics is not publicly available.
Can I buy NeuroAge Therapeutics stock?
NeuroAge Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeuroAge Therapeutics's last funding round?
NeuroAge Therapeutics's most recent funding round was Pre Seed on February 16, 2026.
Who are the main investors in NeuroAge Therapeutics?
Key investors in NeuroAge Therapeutics include Gates Ventures.
Will NeuroAge Therapeutics IPO soon?
No public IPO plans have been announced for NeuroAge Therapeutics.
How can I track NeuroAge Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NeuroAge Therapeutics's shares on secondary markets.